Physician profile
Megan E Andersen
NPI 1760925903
$3,386.92
in general payments reported to CMS, 2019-2025
22 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2022: $405 · 2023: $467 · 2024: $986 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.55 |
| Education | $167.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $867.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $436.04 | 2021-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Otsuka America Pharmaceutical, INC. | $351.69 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $347.59 | 2022-2024 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $307.95 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $225.95 | 2025 | Veozah |
| Abbvie INC. | $166.17 | 2022-2025 | |
| Pfizer INC. | $141.08 | 2024-2025 | |
| Abiomed | $130.50 | 2025 | |
| Inari Medical, INC. | $94.73 | 2021 | |
| Amgen INC. | $55.46 | 2021-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $39.63 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $36.88 | 2022-2023 | |
| Becton, Dickinson and Company | $35.57 | 2025 | Bd Veritor Plus Analyzer |
| Janssen Pharmaceuticals, INC | $32.78 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.47 | 2022 | |
| Merck Sharp & Dohme LLC | $18.47 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.30 | 2022 | |
| Vivus LLC | $16.70 | 2024 | Qsymia |
| Lundbeck LLC | $15.21 | 2025 | Rexulti |
| Medtronic, INC. | $15.20 | 2024 | Venaseal |
| Adlon Therapeutics L.P. | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.